Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs

British Journal of Cancer

Volumn 66, Issue 1, 1992, Pages 198-203

  Cubeddu, L X ^a   Hoffmann, I S ^a   Fuenmayor, N T ^a   Malave, J J ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CISPLATIN; DACARBAZINE; OCTREOTIDE; SEROTONIN; SOMATOSTATIN DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG MECHANISM; ENTEROCHROMAFFIN CELL; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MONOAMINE METABOLISM; NAUSEA; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; VOMITING;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; HYDROXYINDOLEACETIC ACID; NAUSEA; NEOPLASMS; OCTREOTIDE; SEROTONIN; SUPPORT, NON-U.S. GOV'T; VOMITING;

EID: 0026643829     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1992.242     Document Type: Article

References (34)

1. ANDREWS, R. L. R., RAPEPORT, W. G. & SANGER, G. J. (1988). Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacol. Sci., 9, 334-341
2. BARNES, N. M., BARRY, J. M., COSTAL, B., NAYLOR, R. J. & TATTER- SALL, F. D. (1987). Antagonism by parachlorophenylalanine of cisplatin-induced emesis. Br. J. Pharmacol., 92, 649P
3. BERTACCINI, G. (1960). Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestial tract in the rat. J. Physiol., 153, 239-249
4. COSTALL, B., DOMENEY, A. M., NAYLOR, R. J. & TATTERSALL, F. D. (1986). 5-hydroxytryptamine M-receptor antagonism to prevent cisplatinum-induced emesis. Neuropharmacology, 25, 959-961
5. CUBEDDU, L. X., HOFFMANN, I S., FUENMAYOR, N T. & FINN, A. L. (1990a). Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin induced nausea and emesis. N. Engl. J. Med., 322, 810-816
6. CUBEDDU, L. X., HOFFMANN, I S., FUENMAYOR, N. T. & FINN, A. L. (1990b). Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J. Clin. Oncol., 8, 1721-1727. (1990a), 322, 810-816
7. ENCK, R. E. (1977). Mallory-Weiss lesion following cancer chemotherapy. Lancet, 1, 927
8. ERSPAMER, V. (1954). II sistema cellulare enterocromaffine e l’enter- amina (5-idrossitriptamina). R. C. Sci. Farmitalia, 1, 1-193
9. ERSPARMER, V. & TESTINI, A. (1959). Observations on the release and turnover rat of 5-hydroxytryptamine in the gastrointestinal tract. J. Pharm. Pharmacol., 11, 618-623
10. FELDBERG, W. & TOH, C. C. (1953). Distribution of 5-hydroxytrypt- amine (serotonin, enteramine) in the wall of the digestive tract. J. Physiol., 119, 352-362
11. FETTING, J. H., GROCHOW, L. B., FOLSTEIN, M. S., ETTINGER, D. S. & COLVIN, M. (1982). The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat. Rep., 66, 1487-1493
12. FOZARD, J. R. (1987). 5-HT3 receptors and cytotoxic drug-induced vomiting. Trends in Pharmacol. Sci., 8, 44-45
13. GRALLA, R. J., ITRI, L. M. & PISKO, S. E. (1981). Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and emesis. New Engl. J. Med., 305, 905-909
14. GRALLA, R. J., TYSON, L. B., KRIS, M. G. & CLARK, R. A. (1987). The management of chemotherapy-induced nausea and vomiting. Med. Clin. North Amer., 71, 289-301
15. GUNNING, S. J., HAGAN, R. M. & TYERS M. B. (1987). Cisplatin induced biochemical and histological changes in the small intestine of the ferret. Br. J. Pharmacol., 90, 135P
16. HAWTHORN, J., OSTLER, K. J. & ANDREWS, P. L. R. (1988). The role of the abdominal visceral innervation and 5-hydroxytriptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret. Quart. J. Exper. Physiol., 73, 7-21
17. HIGGINS, G. A., KILPATRICK, G. J., BUNCE, K. T., JONES, B. J. & TYERS, M. B. (1989). 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br. J. Pharmacol., 97, 247-255
18. KATZ, M. D. & ERSTAD, B. L. (1989). Octreotide, a new somatostatin analogue. Clin. Pharm., 8, 255-273
19. KILPATRICK, G. H., JONES, B. J. & TYERS, M. B. (1989). Binding of the 5-HT3 ligand, 3H-GR65630, to tar area postrema, vagus nerve and the brains of several species. Eur. J. Pharmacol., 159, 157-160
20. KVOLS, L. K. (1988). The carcinoid syndrome: a treatable malignant disease. Oncology, 2, 33-39
21. LASZLO, J. & LUCAS, V. (1981). Emesis as a critical problem in chemotherapy. N. Engl. J. Med., 305, 948-994
22. LAZLO, J. (1983). Nausea and vomiting as major complications of cancer chemotherapy. In Drugs, Adis Press Ltd: Auckland, N. Z. 25, (Suppl. 1): 1-7
23. LEIBUNDGUT, U. & LANCRANJAN, I. (1987). First results with ICS 205-930 (5-HT, receptor antagonist). Lancet, (May), 1198
24. MARTIN JIMENEZ, M. & DIAZ RUBIO, E. (1985). Curso espontaneo de la emesis inducida por cisplatino y evaluacion preliminar de la metoclopramida en dosis bajas intravenosas. Oncologia, 9, 223-228
25. MARTIN JIMENEZ, M., DIAZ RUBIO, E., SANGRO, B. & MAROTE, R. (1988). Laparotomic eventration of colonic prolapse after chemotherapy-induced emesis. J. Surg. Oncol., 37, 204
26. MARTY, M., POUILLART, P., SCHOLL, S. & others (1990). Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl. J. Med., 322, 816-821
27. MENDELSOHN, J. (1987). Principles of neoplasia. In Principle of Internal Medicine, Braudwald, E., Isselbacher, K. J., Petersdorf, R. G., Wilson, J. D., Martin, J. B. & Fauci, A. S. McGraw Hill, 11th edition, p. 429
28. MINER, W. D. & SANGER, G. J. (1986). Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmacol., 88, 497-499
29. RESNICK, R. H. & GRAY, S. J. (1961). Distribution of serotonin (5- hydroxytryptamine) in the human gastrointestinal tract. Gastroenterology, 41, 119-121
30. SMITH, W. L., JACKSON, C. B., PROAKIS, A. G., LEONARD, C. A., MUNSON, H. R. & ALPHIN, R. S. (1986). Zacopride: a unique and potent inhibitor of cancer-chemotherapy-induced emesis in dogs. Proc. Am. Soc. Clin. Oncol., 5, 1017
31. SMITH, W. L., CALLAHAM, E. M. & ALPHIN, R. S. (1988). The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J. Pharm. Pharmacol, 40, 142-145
32. STABLES, R., ANDREWS, P. L., COSTALL, B. & others (1987). Antiemetic properties of the 5HT3 antagonist, GR38032F. Anticancer Drug Design, 2, 97
33. RESNICK, R. H. & GRAY, S. J. (1961). Distribution of serotonin (5- hydroxytryptamine) in the human gastrointestinal tract. Gastroenterology, 41, 119-121
34. REICHLIN, S. (1985). Somatostatin: parts one and two. N. Engl. J. Med., 309, 2741-1501, 1556-1563